Melanotan I
aka Afamelanotide
Mechanism
Melanotan I (Afamelanotide) is a synthetic analog of alpha-MSH that selectively activates MC1R. FDA-approved as Scenesse for erythropoietic protoporphyria (EPP), it is distinct from Melanotan II and is studied for melanogenesis and photoprotection.
Identification
| CAS number | 75921-69-6 |
|---|---|
| Molecular formula | C78H111N21O19 |
| Sequence | SYSNEHFRWGKPV |
| Typical dose | 16 mg subcutaneous implant every 2 months (approved EPP regimen); research injection doses of 0.08–0.21 mg/kg/day subcutaneous used in early trials |
| Half-life | ~30–50 minutes (plasma elimination half-life after subcutaneous injection; implant formulation releases over ~10 days) |
Vendors selling Melanotan I
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Moglabs | 10 mg | $28.00 | — | 96 |
| Orbitrex Peptides | — | $39.99 | — | 95 |
| Profound Aminos | 10 mg | $59.00 | — | 95 |
| Prime Peptides | 10 mg | $45.00 | — | 95 |
| Peptide Tech | 10 mg | $29.99 | — | 94 |
| Amino Club | — | $29.99 | — | 93 |
| Skye Peptides | 10 mg | $49.00 | — | 90 |
| Peptide Plugs | 10 mg | $40.00 | — | 89 |
| Qihang Peptide | — | — | — | 87 |
| EZ Peptides | 10 mg | $44.00 | — | 85 |
| Peptidegurus | 10 mg | — | — | 84 |
| Ascension Peptides | 10 mg | $50.00 | — | 84 |
| Cocer Peptides | 10 mg | $60.00 | — | 82 |
| Crystal Peptides | 10 mg | $39.99 | — | 66 |
| MJT peptides | 10 mg | $65.00 | — | 39 |
| Cernum Biosciences | 10 mg | $52.99 | — | — |
| Ruo Bio | 10 mg | $28.00 | — | — |
| Alpha Omega | 10 mg | $45.00 | — | — |
| Atomik Labz | 10 mg | $40.00 | — | — |
| Atomik Labz | 10 mg | $29.00 | — | — |
| Bulk Peptides | 10 mg | $140.00 | — | — |
| Felix Chemical Supply | 10 mg | $29.99 | — | — |
| Kimera Chems | — | $46.99 | — | — |
| Oneday Compounds | 10 mg | $39.99 | — | — |
| Polaris Peptides | 13 mg | $50.00 | — | — |
| Solution Peptides | 10 mg | $38.00 | — | — |
| Solution Peptides | 10 mg | $29.00 | — | — |
| Soma Peptides | 10 mg | $49.00 | — | — |
| Southern Aminos | 10 mg | $44.25 | — | — |
| Wellness Peptides | — | $40.00 | — | — |
Research
Objective This systematic review aims to critically assess the literature on the mechanisms of action, clinical uses, formulation strategies, and adverse effects of self-tanning agents, with a focus on dihydroxyacetone (DHA), melanotan, forskolin, and carotenoids.
source →This case report presents a three-month follow-up of a patient who self-administered Melanotan II injections over a period of 64 days with the goal of achieving a deeper tanning effect. Melanotan II is an unlicensed synthetic peptide analog belonging to the melanocortin hormone family.
source →Background Indoor tanning through sunbeds is linked to a heightened risk of skin cancers, particularly cutaneous squamous cell carcinoma and basal cell carcinoma, with significant increases in risk for users aged Objectives To analyse the characteristics, attitudes and behaviours of sunbed users attending an Irish derm…
source →The physiological role of α-melanocyte stimulating hormone in regulating integumental pigmentation of many vertebrate species has been recognized since the 1960's. However, its physiological significance for human pigmentation remained enigmatic until the 1990's.
source →Melanocortins play crucial roles in regulating the stress response, inflammation, and skin pigmentation. In this review, we focus on the melanocortin 1 receptor (MC1R), a G protein-coupled receptor primarily known for regulating skin pigmentation and exhibiting anti-inflammatory effects.
source →Voluntary feed intake is insufficient to meet the nutrient demands associated with late pregnancy in prolific ewes and early lactation in high-yielding dairy cows. Under these conditions, peripheral signals such as growth hormone and ceramides trigger adaptations aimed at preserving metabolic well-being.
source →Purpose The objective of this study was to evaluate in vitro and in vivo the melanogenic activity of one-month duration Melanotan-I (MT-I) implants prepared using poly (D,L lactide-co-glycolide) polymer.
source →A comparative pharmacokinetic trial was performed with a superpotent synthetic melanotropic peptide, [Nle4-D-Phe7]-alpha-MSHi-13 (melanotan-I or MT-I) given by three routes of administration. Plasma levels were measured by RIA and tanning was quantiated using serial reflectometry.
source →The overall objective of these studies was to develop a controlled-release formulation of Melanotan-I (MT-I) containing poloxamer 407 (P407).
source →